Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics (Q37822185)

23 August 2017

1 reference

title

Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics (English)

1 reference

23 August 2017

Una Glamočlija

1

1 reference

PubMed ID

21169132

23 August 2017

Adlija Jevrić-Čaušević

series ordinal

2

1 reference

23 August 2017

1 December 2010

1 reference

23 August 2017

1 reference

23 August 2017

60

1 reference

23 August 2017

4

1 reference

23 August 2017

387-406

1 reference

Type 2 diabetes: principles of pathogenesis and therapy

23 August 2017

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Combining information from common type 2 diabetes risk polymorphisms improves disease prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Neonatal and late-onset diabetes mellitus caused by failure of pancreatic development: report of 4 more cases and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Neonatal diabetes mellitus: a disease linked to multiple mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Inheritance and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Pharmacogenomics and drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Pharmacogenetics of metformin response: a step in the path toward personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Learning from molecular genetics: novel insights arising from the definition of genes for monogenic and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Minireview: pharmacogenetics and beyond: the interaction of therapeutic response, beta-cell physiology, and genetics in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Glucokinase gene mutations: structural and genotype-phenotype analyses in MODY children from South Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

beta-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1alpha and glucokinase mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Defective pancreatic beta-cell glycolytic signaling in hepatocyte nuclear factor-1alpha-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Molecular targets of a human HNF1 alpha mutation responsible for pancreatic beta-cell dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Genetic cause of hyperglycaemia and response to treatment in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1alpha-deficient mice: a mechanism for hypersensitivity to sulfonylurea therapy in patients with maturity-onset diabetes of the young, type 3 (MODY3).

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Identifying hepatic nuclear factor 1alpha mutations in children and young adults with a clinical diagnosis of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1beta

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Contrasting diabetes phenotypes associated with hepatocyte nuclear factor-1alpha and -1beta mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Hnf6 and Tcf2 (MODY5) are linked in a gene network operating in a precursor cell domain of the embryonic pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Gating mechanism of KATP channels: function fits form

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

ATP and sulfonylurea sensitivity of mutant ATP-sensitive K+ channels in neonatal diabetes: implications for pharmacogenomic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Activating mutations in the ABCC8 gene in neonatal diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Pharmacogenetics of glucose-lowering drug treatment: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Sequence variation in PPARG may underlie differential response to troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Effects of the peroxisome proliferator activated receptor-γ coactivator-1α (PGC-1α) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

Targeted deletion of hepatic CTP:phosphocholine cytidylyltransferase alpha in mice decreases plasma high density and very low density lipoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FV10007-010-0040-9

10.2478/V10007-010-0040-9

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21169132